In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains
| Autor: | Maria Trancassini, Gianluca Puggioni, Gabriele Arcari, Valeria Pietropaolo, Alessandra Carattoli, D. M. Rodio, Cecilia Ambrosi, Guido Antonelli, F Stangherlin, Alessia Bressan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Cystic Fibrosis medicine.drug_class 030106 microbiology Immunology Antibiotics Microbial Sensitivity Tests Fosfomycin medicine.disease_cause Cystic fibrosis Microbiology Agar dilution 03 medical and health sciences 0302 clinical medicine medicine Humans Immunology and Allergy fosfomycin mucoid pseudomonas aeruginosa agar dilution automated system 030212 general & internal medicine Automation Laboratory Pseudomonas aeruginosa business.industry medicine.disease In vitro QR1-502 Mucoid Pseudomonas aeruginosa Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization business medicine.drug Infectious agent |
| Zdroj: | Journal of Global Antimicrobial Resistance, Vol 20, Iss, Pp 328-331 (2020) |
| Popis: | Objectives Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation. Fosfomycin does not belong to any other antibiotic class and acts by inhibiting the biosynthesis of the bacterial cell wall during the initial phases. A major problem for the use of fosfomycin against P. aeruginosa is the absence of a clinical breakpoint, the last one of 32 μg/mL was proposed in 2013 by the CA-SFM (Comite de l’Antibiogramme de la Societe Francaise de Microbiologie). Methods Sixty-one strains of P. aeruginosa (thirty mucoid and thirty-one non mucoid) were collected from respiratory samples of cystic fibrosis patients. All isolates were identified by MALDI-TOF (Bruker, Bremen, Germany). Fosfomycin MICs against P. aeruginosa were measured using an automated system and confirmed by the gold standard method. Results There was no significant difference between mucoid and non-mucoid strains. MIC distribution and susceptibility rates were obtained by agar dilution method and from this data we measured MIC50 and MIC90 which were equal to 32 μg/mL and 64 μg/mL, respectively. From automated method results we measured a very major error (VME), major error (ME) and categorical agreement (CA) which were equal to 0%, 11% and 89%, respectively. Comparing automated and agar dilution methods, a Cohen’s kappa equal to 73% (0.726) was measured. Conclusions Our data suggest that fosfomycin has good effect against mucoid and non-mucoid strains of P. aeruginosa and automated systems can be implemented in clinical microbiology laboratories to assess fosfomycin with rapid and reproducible results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|